4.31 USD
▼-0.19-4.22%
盘后 17.82 0.00%
2026-11-20
市值
$30.15M
市盈率
—
EPS
-32.58
股息率
—
52 周区间
2.83 – 45.50
成交量
1.15M
Beta
2.81
目标价
68.67
52W 低 2.8352W 高 45.50
价格走势
公司简介
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company’s lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company’s lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inf...